Search
Mecrylate
go.drugbank.com/drugs/DB21343ExperimentalMecrylate is a small molecule drug. Mecrylate has a monoisotopic molecular weight of 111.03 Da.
Categories: Compounds used in a research, industrial, or household settingEVT 201
go.drugbank.com/drugs/DB05721InvestigationalEVT 201 is a novel partial positive allosteric modulator of the GABAA receptor complex which is being developed as a treatment for insomnia. It is being developed by Evotec Inc.
Rupintrivir
go.drugbank.com/drugs/DB05102ExperimentalRupintrivir was active against all 48 HRV serotypes tested in a cell protection assay in H1-HeLa cells. It is designed to combat colds caused by rhinovirus. … Rupintrivir is a rhinovirus 3C protease inhibitor in development for use against human rhinoviral (HRV) infections.
NOX-100
go.drugbank.com/drugs/DB05799InvestigationalNOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body. … NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.
Lunacalcipol
go.drugbank.com/drugs/DB05024Investigationalsecretion which may be involved in the etiology of psoriasis. … Preclinical studies have shown that CTA018 inhibits the proliferation of rapidly dividing cells such as human epidermal keratinocytes (skin cells) and is also effective in inhibiting pro-inflammatory cytokine
Torcetrapib
go.drugbank.com/drugs/DB06281InvestigationalTorcetrapib (CP-529414, Pfizer) was developed to treat hypercholesterolemia but its development was halted in 2006 when phase III studies showed excessive mortality in the treatment group receiving a combination
Atibuclimab
go.drugbank.com/drugs/DB06546InvestigationalAtibuclimab (IC14) is a chimeric CD14 antibody investigated for the treatment of patients with severe sepsis.
DP-VPA
go.drugbank.com/drugs/DB05821InvestigationalDP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure
Bucrylate
go.drugbank.com/drugs/DB19727ExperimentalBucrylate is a small molecule drug. Bucrylate has a monoisotopic molecular weight of 153.08 Da.
Categories: Compounds used in a research, industrial, or household setting